Rutts tankespinn og ME-nyheter

Det meste av det siste innen biomedisinsk forskning på ME

Tag Archives: biomedisinsk forskning

Forskes på HIV-medisin mot ME

Hentet fra ksl.com:

Videointervju av Dr. Ila R. Sing hvor hun snakker om XMRV, ME og potensiell behandling ved bruk av HIV medisin. Se videoen HER

«Now, in lab cell cultures, Singh and her colleagues have found that one particular drug used to treat AIDS patients also inhibits the same process used by XMRV to convince healthy cells to become villains. The next step: a collaboration with Colorado State University to see what this retrovirus does in animal models.

«First, to see if the virus will replicate, see if it will produce cancer in any form in these animals,» Singh says.

If that happens, if they can see a cause-and-effect link, researchers could then begin testing the HIV drug in combination with others to see if it inhibits or reverses the cancer, and perhaps the neurological byproducts of chronic fatigue syndrome.»

Presentasjon av CFIDS forskning på ME

CFIDS Association of America driver omfattende forskning på ME. Dr. Suzanne D. Vernon, PhD, Scientific Director, holdt 18 februar en presentasjon av pågående forskningsprosjekter.

Se det HER

Artikkel i Science Now om de motstridende XMRV-funnene

«A theory linking chronic fatigue syndrome (CFS) to an infectious mouse virus known as XMRV has taken a second major hit. Firstproposed last October in Science, the virus-CFS connection was quickly challenged by a British group. Now a second team of British virologists reports that, after examining tissue from 170 CFS patients, they have failed to find evidence of XMRV.»

Les hele artikkelen HER

CFIDS analyse av det siste XMRV-studie fra England

Suzanne D. Vernon, PhD, Scientific Director hos CFIDS har kommet med en analyse av det siste XMRV-studie fra England.

«The Retrovirology study found evidence of XMRV by detecting specific antibodies in samples from study subjects, demonstrating that XMRV has infected people. But like the other study from the U.K. reported in PLoS ONE, this study did not detect XMRV at a higher rate in people with CFS. Why? The PCR technique used in the paper was identical to the Science paper and other methods they used could be considered better and more sensitive. The antibodies used by the two labs were different, though. These investigators did not test quite as many healthy control blood samples (157 in the SGUL cohort) as did the authors of the Science paper (218 healthy controls), which found XMRV in 3.7% of healthy controls. (The source of healthy control samples was not described in the Science paper.) Perhaps more important is that this Retrovirology paper tested for XMRV in healthy blood donors; blood donors are screened for many things and are likely to be a much healthier group than controls obtained from the general population. The inclusion of the BLT comparison group of individuals with other conditions was new for this study.

Why wasn’t XMRV DNA found in the CFS samples? One difference between the CFS patients selected for the SGUL cohorts and those tested in the Science paper might be severity and duration of illness. The SGUL CFS cohort blood samples were taken relatively early in course of CFS (1-4 years). The CFS patients in the Science paper were severely ill in addition to having immune dysfunction, although specific characteristics have not been released. It could simply be that the CFS patients in the SGUL cohorts were not comparable (e.g., as sick as long) to those studied in the Science paper. However, Dr. Kerr’s reputation and experience in CFS/ME research, along with his current collaborations with the Whittemore Peterson Institute, suggest that he would have taken care to use similar selection criteria in his design of the study. (It is noted in the acknowledgements that “JK” – Jonathan Kerr – was one of the three authors who conceived of and designed the study.)»

Les hele analysen HER

Nyeste XMRV-studie brukte IKKE WPIs metoder

En bloggpost skrevet av Vincent Racaniello, PhD, professor of microbiology at Columbia University Medical Center:

«This does not eliminate a role for XMRV in CFS.»

Les hele stykket HER

CNRS-Institut i Paris publiserer ny forskning om det ME assosierte retroviruset XMRV

Tatt fra pressemeldingen hos National Academy of Sciences USA:

«In conclusion, our work demonstrates the critical role of Env-induced immunosuppression for retrovirus propagation in vivo and identifies a unique definite target for antiretroviral therapies and vaccine strategies, also characterized in the human T-cell leukemia virus (HTLV) and xenotropic murine leukemia virus-related virus (XMRV) retroviruses, opening unprecedented prospects for the treatment of retroviral diseases.»

Link til publisering HER

Link til pressemelding HER

Webinar med Suzanne D. Vernon 18.02.10

CFIDS arrangerer nytt webinar:

Association Research Program Update
Speaker: Suzanne D. Vernon, PhD, Scientific Director
Date: Thursday, February 18, 2010
Time: 2:00-3:30 (Eastern Standard Time)
Registration: https://www1.gotomeeting.com/register/668153665

Norsk tid er 20.00 – 20.30. Du må registrere deg for å få delta, klikk på linken ovenfor.

Vil du være med å bidra til biomedisinsk ME-forskning?

Fra WPIs webside:

«For a donation of as little as $60.00 per year, you can become a «Friend of the Institute.» You will receive a beautiful WPI Butterfly logo pin, invitations to WPI events, our newsletter and special email updates.»

Les mer her

Dr. Kerr medlem i Europan Society for ME

Klippet fra European Society for ME (ESME) hjemmeside:

«The European Society for ME (ESME) is pleased to welcome Dr. Jonathan Kerr as an honorary member. Dr. Kerr is a much respected ME/CFS researcher. He has participated in many ME/CFS conferences, where he has presented important findings,especially concerning genomic subtypes in ME/CFS patients.

He currently works at St. George’s University in London where he and his team are examining the role of XRMV in modulaton of NK cell cytotoxicity and NK cell gene abnormalities in ME/CFS patients and normal blood donors.

He is also collaborating with the Whittemore Peterson Institute in a study to develop diagnostic biomarkers in order to predict response to immune modulating therapy and vaccines.»

Les hele artikkelen og mer om Dr. Kerr  her

WPI har oppdatert XMRV-test og lisensiert den til labratoriet VipDX

Pressemelding fra WPI publisert på WPIs Facebook side:

Whittemore Peterson Institute Announces Availability of Updated XMRV Testing
Reno, Nev. – In October 2009, together with the Cleveland Clinic and National Cancer Institute,
the Whittemore Peterson Institute published findings in Science regarding the discovery of
XMRV in the blood of Chronic Fatigue Syndrome (CFS) patients. The testing method, validated
in multiple other labs using positive control samples, uses a unique process that was extensively
peer reviewed before publication and provides the most accurate results available.
This virus culture test is the same method used in the Science publication, and the only
scientifically validated methodology to find XMRV. Some labs, including the recent study
published in the U.K., have used non-validated PCR and whole blood PCR assays. At this time
no single PCR or whole blood assay alone has been validated as accurately detecting XMRV,
and is therefore not an appropriate way to study or diagnose the presence of the virus.
WPI has licensed the latest version of the test to Viral Immune Pathways Diagnostic
Laboratories (VIP Dx) in Reno, Nev. The non-exclusive license allows patients and their doctors
access to a reliable diagnostic tool. The newly refined test uses a virus culture methodology that
yields more reliable results in one test at a lower cost to patients.
“Our mission at WPI is to discover bio markers of disease and translate those discoveries into
accurate diagnostics and effective treatments for patients,” said WPI Founder and President
Annette Whittemore. “We continue to talk to other clinical laboratory companies, both nationally
and internationally, in order to make the test available to a wider audience.”
WPI Research Scientist and co-author of the Science paper, Dr. Vincent Lombardi, is providing
technical assistance and oversight of the VIP Dx testing. In exchange for the non-exclusive
license, VIP Dx will pay a royalty to WPI for each test it conducts.
Continued
“We structured the licensing contract to be sure that any and all profits that might emerge at VIP
Dx from XMRV testing come directly back to WPI to benefit the research program” said
Whittemore.
Dr. Lombardi is an employee of WPI, and has no personal financial interest in VIP Dx.
Likewise, the Whittemore family put their interest in VIP Dx into a trust to benefit WPI.
The availability of these tests has a dramatic impact to the CFS/ME community. These tests
allow licensed laboratories to begin answering important questions about XMRV’s incidence in
disease and prevalence in the world. WPI hopes that this will generate further research related to
XMRV. «The institutes’ driving goal continues to be the translation of research to meaningful
results for patients, explained Whittemore.
It is still unknown exactly how XMRV impacts humans. Scientists who understand the potential
ramifications of human infection with retroviruses take the study of XMRV seriously. WPI
researchers along with many other scientists around the world are actively engaged in advancing
research in this field.
Whittemore Peterson Institute
The Whittemore Peterson Institute for Neuro-Immune Disease exists to bring discovery, knowledge,
and effective treatments to patients with illnesses that are caused by acquired dysregulation of the
immune system and the nervous system, often results in lifelong disease and disability. The WPI is
the first institute in the world dedicated to X associated neuro-immune disease (XAND), and other X
associated diseases, integrating patient treatment, basic and clinical research and medical
education.

Du kan bruke Google oversetter for å lese pressemeldingen på norsk her .